Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

7/16/24 1:13:51 AM ET

$ARGX

$ZLAB

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ARGX alert in real time by email

First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China
Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study

Get the next $ARGX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARGX
$ZLAB

Company	Date	Price Target	Rating	Analyst
argenx SE $ARGX	11/12/2024	$697.00	Peer Perform → Outperform	Wolfe Research
argenx SE $ARGX	11/5/2024	$715.00	Sector Perform → Sector Outperform	Scotiabank
argenx SE $ARGX	11/1/2024	$515.00 → $650.00	Outperform → Neutral	Robert W. Baird
argenx SE $ARGX	11/1/2024		Mkt Perform → Outperform	William Blair
argenx SE $ARGX	10/10/2024	$605.00	Strong Buy	Raymond James
argenx SE $ARGX	10/4/2024		Buy → Hold	Deutsche Bank
argenx SE $ARGX	8/6/2024		Equal Weight → Overweight	Barclays
argenx SE $ARGX	7/25/2024		Hold → Buy	Deutsche Bank

More analyst ratings

$ARGX
$ZLAB
Financials

Live finance-specific insights

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT in schizophrenia; expected regulatory submission in early 2025 Global Phase 1 data of ZL-1310 (DLL3 ADC) suggests best-in-class potential in extensive-stage SCLC Three product launches in mainland China expected by the end of 2024, and up to four potential regulatory submissions to the NMPA in the next six months Strong balance sheet with a cash position1 of $716.1 million as of September 30, 2024, compared to $730.0 million as of June 30, 2024 Conference call and webcast today, November 12, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab L
11/12/24 6:30:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated information - Inside information October 31, 2024 7:00AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2024 financial results and provided a business update. "We delivered significant patient impact with VYVGART over the quarter, expanding our gMG footprint and delivering inn
10/31/24 2:00:00 AM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
-- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK) and safety profile support continued evaluation of ZL-1310 as a single agent and in combination for the treatment of extensive-stage SCLC in recurrent and first-line therapy -- Zai Lab to host conference call and webcast to discuss data on October 24, 2024, at 8:30 a.m. ET, following presentation of the data at ENA Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC)
10/24/24 5:15:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in
6/11/24 4:05:00 PM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f
1/16/23 1:30:00 PM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt
1/9/23 7:30:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Zai Lab (("Zai Lab", NASDAQ:ZLAB, HKEX: 9688)) and Pfizer (("Pfizer", NYSE:PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to help accelerate access to this important therapy for patients in need in mainland China. The period of collaboration is for the imported product through Novem
11/21/24 4:00:00 AM ET
$PFE
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study in adults with idiopat
11/20/24 1:00:00 AM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ:ZLAB, HKEX: 9688)), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares ("ADSs"), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. In addition, Zai Lab today announced that the underwriters in the offering fully exercised their option to purchase an additional 1,176,470 ADSs at the public offering price, less underwriting discounts and commissions. The sale of additional ADSs pursuant to the exercise of the option to purchase additional ADSs is expected to clos
11/18/24 9:15:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care

Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

Chat with this insight

Recent Analyst Ratings for $ARGX$ZLAB

$ARGX$ZLAB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

argenx upgraded by Wolfe Research with a new price target

argenx upgraded by Scotiabank with a new price target

argenx downgraded by Robert W. Baird with a new price target

$ARGX$ZLAB Financials

Live finance-specific insights

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

$ARGX$ZLAB Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by argenx SE

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by argenx SE

$ARGX$ZLAB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Chen Yajing converted options into 500 units of American Depositary Shares and sold $5,121 worth of American Depositary Shares (167 units at $30.66), increasing direct ownership by 2% to 15,494 units (SEC Form 4)

Chief Financial Officer Chen Yajing converted options into 920 units of American Depositary Shares and sold $7,645 worth of American Depositary Shares (301 units at $25.40), increasing direct ownership by 4% to 15,161 units (SEC Form 4)

Director Gaynor Richard sold $48,750 worth of American Depositary Shares (2,500 units at $19.50), decreasing direct ownership by 5% to 46,568 units (SEC Form 4)

$ARGX$ZLAB Market Insights

Live Market Insights

Argenx shares are trading higher after the company reported better-than-expected Q2 GAAP EPS and sales.

For 2024 argenx Expects To Spend Less Than $2B On Expenses And Under $500M In Net Cash For Operations

argenx Q2 2024 GAAP EPS $0.45 Beats $(0.98) Estimate, Sales $489.428M Beat $439.217M Estimate

$ARGX$ZLAB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

$ARGX$ZLAB Leadership Updates

Live Leadership Updates

$ARGX$ZLAB Press Releases

Fastest customizable press release news feed in the world

$ARGX$ZLAB SEC Filings

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

SEC Form 6-K filed by argenx SE

SEC Form 8-K filed by Zai Lab Limited

SEC Form 424B5 filed by Zai Lab Limited

Recent Analyst Ratings for
$ARGX
$ZLAB

$ARGX
$ZLAB
Analyst Ratings

$ARGX
$ZLAB
Financials

$ARGX
$ZLAB
Large Ownership Changes

$ARGX
$ZLAB
Insider Trading

$ARGX
$ZLAB
Market Insights

$ARGX
$ZLAB
Insider Purchases

$ARGX
$ZLAB
Leadership Updates

$ARGX
$ZLAB
Press Releases

$ARGX
$ZLAB
SEC Filings